Neoplasia/BPH

	Darolutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase 3 ARANOTE Trial. Eur Urol Saad F, Shore N, Vjaters E, Olmos D, Littleton N, Testa I, Mo M, Verholen F, Srinivasan S, Haresh KP. PMID: 42586872 [PubMed - as supplied by publisher]
	Enhancer Collapse Dictates PKHD1 Silencing and Centrosome-Mediated Chromosomal Instability and Metastasis in Clear Cell Renal Cell Carcinoma. Exp Cell Res Wang Y, Wang L, Deng J, Tian Z, Liang Z, Zhang H. PMID: 42586231 [PubMed - as supplied by publisher]
	Beyond the "Swan Song": Salvage Stereotactic Body Radiation Therapy for Nodal Oligorecurrence in Previously Irradiated Prostate Cancer - Lessons From the CYGNUS Retrospective Study. Int J Radiat Oncol Biol Phys Vial N, Dess RT, Zilli T. PMID: 42586129 [PubMed - in process]
	Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial. Lancet Motzer RJ, McDermott R, Park SH, Burotto M, Iacovelli R, Verzoni E, Suárez C, Eto M, Cutuli HJ, Porta C, Kopp RM, Rottey S, Velasco G, Valderrama BP, Azad AA, Giorgi U, Pavic M, Tomczak P, Figlin R, Westgeest HM, Guida A, Necchi A, Schutz FA, Suelmann BBM, Haanen JBAG, Yuan SS, Perini RF, Wang D, Heng DYC, Schmidinger M, LITESPARK-011 Investigators. PMID: 42586114 [PubMed - as supplied by publisher]
	Integrated Methylation and Copy Number Analysis for Noninvasive Bladder Cancer Detection in Urine. JCO Precis Oncol Beijert IJ, Wever BMM, Moldovan N, van den Burgt Y, Nouwens A, van der Pol Y, Hentschel AE, Bosschieter J, Lissenberg-Witte B, Kauer PC, van Moorselaar RJA, Mouliere F, Nieuwenhuijzen JA, Steenbergen RDM. PMID: 42585615 [PubMed - indexed for MEDLINE]
	Succinic Acid-Sunitinib Combination Treatment Downregulates the Angiogenic Gene Expressions in Sunitinib- Resistant Renal Cancer Cell Line. Cell Biochem Biophys Ertugrul B, Kavsara GK, Bireller S, Ergen A, Cakmakoglu B. PMID: 42584757 [PubMed - as supplied by publisher]
	Intravesical Recurrence of Upper Tract Urothelial Carcinoma: Strategies for Prevention. Curr Urol Rep Song L, Meagher M, Saidian A, Salmasi A, Azari S, Dabbas M, Bagrodia A. PMID: 42584515 [PubMed - indexed for MEDLINE]
	Editorial Comment to "Perioperative Systemic Treatment Patterns and Postoperative Mortality Among Patients With Muscle-Invasive Bladder Cancer Undergoing Radical Cystectomy in Japan: WAKKA-MIBC Study". Int J Urol Watanabe R. PMID: 42583697 [PubMed - in process]
	Economic Insecurities and Patient-Reported Outcomes Among Cancer Survivors after Receiving External Beam Radiotherapy for Prostate Cancer: A Cross-sectional Study. Urol Nurs González-Mercado VJ, Hu J, Marrero SJ, Clark-Cutaia MN. PMID: 42583486 [PubMed]
	Machine learning-derived mast cell-associated angiogenesis features can serve as prognostic targets for clear cell renal cell carcinoma. Transl Androl Urol Ji R, Dai H, Zhang X, Kong W, Zhang J, Wang Y, Wang J, Tang L, Cao X, Liu Y, Qin C. PMID: 42582947 [PubMed]
	Development and internal validation of a noninvasive predictive model based on iron and fat measurements for pathologic risk stratification in prostate cancer. Transl Androl Urol Li Z, Zhao Y, Zhu M, Tian Z, Han S, Li Y, Li G. PMID: 42582923 [PubMed]
	NECSO-based classification predicts immunotherapy efficacy and identifies FLAD1 as therapeutic target in kidney renal clear cell carcinoma. Front Immunol Pan Y, Wu R, Zhu X, Hu X, Cheng J, Kong L. PMID: 42582320 [PubMed - indexed for MEDLINE]
	Immunological and inflammatory biomarkers of localized and locally advanced prostate cancer treated with radiotherapy. Front Immunol Ka K, Niang DGM, Faye MD, Thiam J, Sargos P, Bossi A, Terlizzi M, Jalloh M, Sine B, Dieng MM, Ka S, Mbengue B. PMID: 42582310 [PubMed - indexed for MEDLINE]
	Efficacy and safety of combination versus single-agent immunotherapy for BCG-unresponsive non-muscle-invasive bladder cancer. Front Immunol Zhou Y, Yang X, Tian T, Yang B, Cheng J, Liu Y, Tang D, Liu Y, Li Y, Wang F. PMID: 42582256 [PubMed - indexed for MEDLINE]
	Retraction notice to "A novel immunosensor for the monitoring of PSA using binding of biotinylated antibody to the prostate specific antigen based on nano-ink modified flexible paper substrate: efficient method for diagnosis of cancer using biosensing technology" [Heliyon 6 (2020) e04327]. Heliyon Farshchi F, Saadati A, Hasanzadeh M. PMID: 42581872 [PubMed]
	Deep learning-assisted detection of lymph node metastases in bladder cancer. Diagn Pathol Gorczynski A, Tarján B, Neittaanmäki N. PMID: 42581380 [PubMed - indexed for MEDLINE]
	Urinary multi-omics reveal non-invasive diagnostic biomarkers in clear cell renal cell carcinoma. EMBO Mol Med Jonsson G, Oliveira T, Hofmann M, Lemberger U, Stejskal K, Kr, Sakic I, Novatchkova M, Mereiter S, Grabmann G, Köcher T, Koglgruber R, Kikic Z, Camano Páez S, Luna Sanchez B, Díez Nicolás V, Rechberger GN, Züllig T, Hagelkruys A, Englinger B, Schmidinger M, Penninger JM. PMID: 42581140 [PubMed - as supplied by publisher]
	Prostate cancer: evading immunity, inspiring therapy. Trends Cancer Calì B, Brina D, Moscarda V, Kohl A, Cetti F, Bressan S, Alimonti A. PMID: 42580969 [PubMed - as supplied by publisher]
	PSMA Radio-guided Surgery to Identify Lymph Node Metastases in Prostate Cancer Patients Undergoing Robot-assisted Radical Prostatectomy and Extended Pelvic Lymph Node Dissection: Results of a Phase 2 Prospective Study. Eur Urol Quarta L, Zaurito P, Viti A, Cosenza A, Scuderi S, Barletta F, Cucchiara V, Stabile A, Dambrosio L, Mazzone E, Tenace N, Brembilla G, De Cobelli F, Gajate AMS, Pini C, Picchio M, Chiti A, Montorsi F, Briganti A, Gandaglia G. PMID: 42580956 [PubMed - as supplied by publisher]
	Expanding indications for PARP inhibitors in prostate cancer. Urol Oncol Kowalewski HS, Wessels F, Banna GL, Gandur Quiroga MN, Zschäbitz S. PMID: 42580914 [PubMed - as supplied by publisher]

Articles 1 - 20 / 190428

Page 1 of 9522



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy